Shopping Cart
- Remove All
- Your shopping cart is currently empty
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody), a humanized monoclonal antibody, selectively neutralizes IL-17A and IL-17F, which promote osteogenic differentiation in human periosteum-derived cells (hPDC), and consequently inhibits inflammation-driven osteogenic differentiation [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $372 | 6-8 weeks | |
5 mg | $787 | 6-8 weeks | |
10 mg | $1,230 | 6-8 weeks |
Description | Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody), a humanized monoclonal antibody, selectively neutralizes IL-17A and IL-17F, which promote osteogenic differentiation in human periosteum-derived cells (hPDC), and consequently inhibits inflammation-driven osteogenic differentiation [1]. |
Cas No. | 1418205-77-2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.